MYBMIM

Cat. No.:	HY-P10238
Molecular Formula:	$C_{166}H_{296}N_{60}O_{45}S$
Molecular Weight:	3884.57
Sequence:	Ac-d-{Lys-Leu-Glu-Asn-Glu-Thr-Ser-Met-Leu-Leu-Leu-Glu-Leu-Glu-Lys-Ile-Arg-Lys-Gly-Gly-Arg-Arg-Arg-Gln-Arg-Arg-Lys-Lys-Arg-Gly-Tyr}-NH2
Sequence Shortening:	Ac-d-{KLENETSMLLLELEKIRKGG-RRRQRRKKRGY}-NH2
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

MYBMIM is an inhibitor for assembly of the molecular MYB:CBP/P300 complex. MYBMIM inhibits growth of leukemia cells[1].

In Vitro

MYBMIM (10-20 μM) inhibits proliferation (6 days) and induces apoptosis (48 h) in acute myeloid leukemia cells by downregulating anti-apoptotic Bcl2 gene expression[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	MOLM-13, MV-411, ML2, and HL60
Concentration:	10-20 μM
Incubation Time:	6 days
Result:	Inhibited cell viability.

Apoptosis Analysis[1]

Cell Line:	MV-411
Concentration:	20 μM
Incubation Time:	4 h
Result:	Induced cell apoptosis.

Western Blot Analysis[1]

Cell Line:	MOLM-13, MV-411, ML2, and HL60
Concentration:	10-20 μM
Incubation Time:	6 h
Result:	Downregulated levels of Bcl2

In Vivo

MYBMIM (25 mg/kg, ip, twice a day for 14 days) impedes human leukemia progression in mouse xenograft models[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	AML-MLL- leukemia xenograft mice model[1]
Dosage:	25 mg/kg
Administration:	ip, twice a day for 14 days
Result:	Delayed leukemia progression and extended survival.

REFERENCES

[1]. Ramaswamy K, et al., Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat Commun. 2018 Jan 9;9(1):110.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA